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Objective
In tumor microenvironment, CD4+CD25+CD127dim/-
Regulatory T cells (Treg cells) belong to a group of
negative regulatory cells, which play an important role
in the mechanism of immune inhibition and immune
escape of liver cancer [1]. In this study, we will explore
the mechanism of Treg cells increasing the growth of
HepG2 cells.
Methods
Treg cells were isolated by immunomagnetic beads from
peripheral blood of patients with hepatocellular carci-
noma. The proliferation of HepG2 cells was determined
by MTT assay. Flow cytometry was employed to detect
the cell cycle distribution and the expression of RANK,
RANKL on cells. The real time quantitative PCR was per-
formed to detect the gene expression and Western blot
was performed to test the level of protein. The cytokines
in the cultured supernatant were tested with protein chip.
Results
Treg cells were isolated from peripheral blood with the
purity (93.83 ± 1.97) %. The proliferation rate of HepG2
cells was upregulated significantly while co-cultured with
Treg cells, and the G1 ratio of HepG2 cells decreased, but
S and G2 ratio increased. After co-cultured with Treg
cells, the expression cyclin B and CDK1 gene of HepG2
cells were increased while the expression of P21 gene was
decreased. It was also found that the Cyclin A, cyclin B
and CDK1 protein level in HepG2 cells were increased
while P21 was decreased. More interesting, the expression
of RANKL on Treg cell was upregulated to (94.61 ± 1.56)
%, and the RANK on HepG2 cell was to (96.88 ± 2.76) %
in the co-culture system. The expression of IL-6, IL6R,
sgp130 IL-17, TGF-b in the supernatant was increased
significantly at the same time.
Conclusion
Treg cells could change the cell cycle of HepG2 cells, and
enhance the proliferation of HepG2 cells by RANK-
RANKL pathway, as well as by upregulating the level of
cytokines like IL-6 and IL-17. Treg might be a target to
reverse the inhibitory immune microenvironment, and
inhibit the growth of hepatocellular carcinoma
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